Cartesian Therapeutics, Inc. (United States)

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 2016-01-01

Employees: 11

Market Cap: $300.2M

Website: http://www.cartesiantherapeutics.com

Clinical Trials

Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma

Phase 1

Recruiting

Conditions: Refractory Multiple Myeloma
Relapsed Multiple Myeloma

Interventions: Drug: Descartes-15

First Posted Date: 2024-03-12

Last Posted Date: 2024-08-02

Lead Sponsor: Cartesian Therapeutics

Target Recruit Count: 41

Registration Number: NCT06304636

Locations: 🇺🇸
Center for Cancer and Blood Disorders (AON), Bethesda, Maryland, United States

Descartes-08 for Patients With Systemic Lupus Erythematosus

Phase 2

Recruiting

Conditions: Systemic Lupus Erythematosus (SLE)

Interventions: Drug: Descartes-08

First Posted Date: 2023-09-14

Last Posted Date: 2024-02-28

Lead Sponsor: Cartesian Therapeutics

Target Recruit Count: 30

Registration Number: NCT06038474

Locations: 🇺🇸
Profound Research LLC, Oceanside, California, United States

Descartes-25 in Relapsed/Refractory Multiple Myeloma

Phase 1

Terminated

Conditions: Relapse Multiple Myeloma
Multiple Myeloma

Interventions: Drug: Descartes-25

First Posted Date: 2021-11-09

Last Posted Date: 2024-11-12

Lead Sponsor: Cartesian Therapeutics

Target Recruit Count: 9

Registration Number: NCT05113342

Locations: 🇺🇸
Louisiana State University Health Science Center at Shreveport, Shreveport, Louisiana, United States
🇹🇷
Saglik Bilimleri Universitesi, Ankara, Anatolia, Turkey
🇺🇸
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States

Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

Phase 2

Terminated

Conditions: Myeloma Multiple

Interventions: Biological: Descartes 08

First Posted Date: 2021-03-25

Last Posted Date: 2024-10-08

Lead Sponsor: Cartesian Therapeutics

Target Recruit Count: 13

Registration Number: NCT04816526

Locations: 🇺🇸
University of California Irvine, Orange, California, United States
🇺🇸
Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee, United States

Study of Descartes-30 in Acute Respiratory Distress Syndrome

Phase 1

Terminated

Conditions: Acute Respiratory Distress Syndrome
Covid19

Interventions: Biological: Descartes 30

First Posted Date: 2020-08-24

Last Posted Date: 2024-10-29

Lead Sponsor: Cartesian Therapeutics

Target Recruit Count: 12

Registration Number: NCT04524962

Locations: 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸
University of Maryland Medical Center Medical Center, Baltimore, Maryland, United States

Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Biological: Descartes 11

First Posted Date: 2020-06-17

Last Posted Date: 2024-12-03

Lead Sponsor: Cartesian Therapeutics

Target Recruit Count: 5

Registration Number: NCT04436029

Locations: 🇺🇸
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
🇺🇸
Stephenson Cancer Center Oklahoma University Health Science Centers, Oklahoma City, Oklahoma, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 1 locations

Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

Phase 2

Recruiting

Conditions: Myasthenia Gravis, Generalized

Interventions: Drug: Descartes-08

First Posted Date: 2019-10-31

Last Posted Date: 2024-05-24

Lead Sponsor: Cartesian Therapeutics

Target Recruit Count: 30

Registration Number: NCT04146051

Locations: 🇺🇸
Profound Research, Carlsbad, California, United States
🇺🇸
University of Kansas Medical Center Research Institute, Kansas City, Kansas, United States
🇺🇸
University of California Irvine, Irvine, California, United States

and more 12 locations

Descartes-11 in Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Biological: Descartes-11
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2019-06-21

Last Posted Date: 2024-10-01

Lead Sponsor: Cartesian Therapeutics

Target Recruit Count: 25

Registration Number: NCT03994705

Locations: 🇺🇸
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
🇺🇸
Medical College of Wisconsin, Madison, Wisconsin, United States

Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Biological: Descartes-08
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2018-02-28

Last Posted Date: 2024-07-01

Lead Sponsor: Cartesian Therapeutics

Target Recruit Count: 32

Registration Number: NCT03448978

Locations: 🇺🇸
The Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
🇺🇸
Virgina Cancer Specialists, Fairfax, Virginia, United States

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy